Souhaitez-vous accéder aux communiqués récents ?

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and...

Inmazeb® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically...

TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated...

Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal or...

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform  Agreement provides for Parabilis to receive $125M from...

The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the...

Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

Regeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years Recognition complements the company’s recent announcement that it will provide its new gene therapy...

Dupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural changes and inflammation in the esophagus in adult patients...

First quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025Dupixent® global net sales (recorded by Sanofi) increased 33% to $4.9 billion EYLEA HD® U.S. net sales increased 52%...